[go: up one dir, main page]

WO2013155528A3 - Methods for reducing brain inflammation, increasing insulin sensitivity, and reducing ceramide levels - Google Patents

Methods for reducing brain inflammation, increasing insulin sensitivity, and reducing ceramide levels Download PDF

Info

Publication number
WO2013155528A3
WO2013155528A3 PCT/US2013/036639 US2013036639W WO2013155528A3 WO 2013155528 A3 WO2013155528 A3 WO 2013155528A3 US 2013036639 W US2013036639 W US 2013036639W WO 2013155528 A3 WO2013155528 A3 WO 2013155528A3
Authority
WO
WIPO (PCT)
Prior art keywords
reducing
formula
methods
insulin sensitivity
increasing insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2013/036639
Other languages
French (fr)
Other versions
WO2013155528A2 (en
Inventor
Joseph William MCFADDEN
Gabriele Valeria RONNETT
Susan Aja SLOAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
FASgen Inc
Original Assignee
FASgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by FASgen Inc filed Critical FASgen Inc
Publication of WO2013155528A2 publication Critical patent/WO2013155528A2/en
Publication of WO2013155528A3 publication Critical patent/WO2013155528A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Methods for reducing brain inflammation, increasing insulin sensitivity, and reducing ceramide levels in a subject including by administering one or more compounds of Formula I, Formula II, or both are provided. The present disclosure provides for, and includes the use of a compound of Formula I, Formula II, or both for the manufacture of a medicine for reducing inflammation. In certain aspects, the compound of Formula I is FSG67 and the compound of Formula II is C75. The present disclosure also provides for, and includes, the use of a compound of Formula I, Formula II, or both for the manufacture of a medicine for the activation of palmitate oxidation in a subject in need.
PCT/US2013/036639 2012-04-13 2013-04-15 Methods for reducing brain inflammation, increasing insulin sensitivity, and reducing ceramide levels Ceased WO2013155528A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261623896P 2012-04-13 2012-04-13
US61/623,896 2012-04-13

Publications (2)

Publication Number Publication Date
WO2013155528A2 WO2013155528A2 (en) 2013-10-17
WO2013155528A3 true WO2013155528A3 (en) 2013-12-05

Family

ID=49328292

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/036639 Ceased WO2013155528A2 (en) 2012-04-13 2013-04-15 Methods for reducing brain inflammation, increasing insulin sensitivity, and reducing ceramide levels

Country Status (1)

Country Link
WO (1) WO2013155528A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015066035A1 (en) * 2013-10-28 2015-05-07 The Forsyth Institute Compositions and methods for evaluating metabolic syndrome and related diseases
SG11201604611SA (en) 2013-12-18 2016-07-28 Glaxosmithkline Ip Dev Ltd Nrf2 regulators
KR101705253B1 (en) * 2014-10-06 2017-02-22 울산과학기술원 Pharmaceutical composition for prevention or treatment of inflammatory diseases comprising cerulenin or cerulenin derivative as an active ingredient
EP3220901B1 (en) 2014-11-20 2020-02-19 VIB vzw Means and methods for treatment of early-onset parkinson's disease
ES2910938T3 (en) 2015-06-15 2022-05-17 Glaxosmithkline Ip Dev Ltd NRF2 regulators
PT3307739T (en) 2015-06-15 2021-01-04 Glaxosmithkline Ip Dev Ltd Nrf2 regulators
US10364256B2 (en) 2015-10-06 2019-07-30 Glaxosmithkline Intellectual Property Development Limited Biaryl pyrazoles as NRF2 regulators
CN118103038A (en) * 2021-08-20 2024-05-28 英安塔制药有限公司 17β-Hydroxysteroid Dehydrogenase Type 13 Inhibitors and Methods of Use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033506A1 (en) * 2001-11-30 2004-02-19 Dennis Farrelly Polynucleotides encoding novel human mitochondrial and microsomal glycerol-3-phosphate acyl-transferases and variants thereof
US20050106217A1 (en) * 2002-02-08 2005-05-19 Johns Hopkins University Licensing And Technology Development Stimulation of CPT-1 as a means to reduce weight
US20110274654A1 (en) * 2010-05-05 2011-11-10 Bahadoor Adilah Triazoles as inhibitors of fatty acid synthase
US20120083471A1 (en) * 2008-07-07 2012-04-05 Townsend Craig A Novel Compounds, Pharmaceutical Compositions Containing Same, Methods of Use for Same, and Methods for Preparing Same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033506A1 (en) * 2001-11-30 2004-02-19 Dennis Farrelly Polynucleotides encoding novel human mitochondrial and microsomal glycerol-3-phosphate acyl-transferases and variants thereof
US20050106217A1 (en) * 2002-02-08 2005-05-19 Johns Hopkins University Licensing And Technology Development Stimulation of CPT-1 as a means to reduce weight
US20120083471A1 (en) * 2008-07-07 2012-04-05 Townsend Craig A Novel Compounds, Pharmaceutical Compositions Containing Same, Methods of Use for Same, and Methods for Preparing Same
US20110274654A1 (en) * 2010-05-05 2011-11-10 Bahadoor Adilah Triazoles as inhibitors of fatty acid synthase

Also Published As

Publication number Publication date
WO2013155528A2 (en) 2013-10-17

Similar Documents

Publication Publication Date Title
WO2013155528A3 (en) Methods for reducing brain inflammation, increasing insulin sensitivity, and reducing ceramide levels
JP2012107034A5 (en)
BR112014031806A8 (en) gd2 positive cancer treatment method
EP3682875A3 (en) Methods of treating pediatric metabolic syndrome
EP2702994A3 (en) Methods of administering pirfenidone therapy
ZA201503110B (en) Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
WO2013170068A3 (en) Nuclear transport modulators and uses thereof
WO2012149299A3 (en) Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
WO2014205389A8 (en) Nuclear transport modulators and uses thereof
MX356728B (en) Pharmaceutical combination for use in the treatment of diabetes type 2.
WO2013028818A8 (en) Pyrimido- pyridazinone compounds and use thereof
MX2015011359A (en) Macrocyclic lrrk2 kinase inhibitors.
MX2013011124A (en) Compounds for treatment of metabolic syndrome.
WO2014160281A3 (en) Method of enhancing delivery of therapeutic compounds to the eye
EP3013219A4 (en) Low glucose treatment for people with diabetes
PH12014502071A1 (en) Beta-hydroxy-beta-methylbutyric acid for imrpoving glucose tolerance
BR112014032169A2 (en) therapeutic treatments with anti-her2 antibodies having low fucosylation
HK1222328A1 (en) Perforin-2 activators and inhibitors as drug targets for infectious disease and gut inflammation
MX2014014814A (en) Pharmaceutical composition for treating inflammation and pain.
WO2013090319A3 (en) Treatment of type i and type ii diabetes
WO2013111013A8 (en) Methods for treating alzheimer's disease by administering certain synthetic compounds
WO2012145234A3 (en) Cyclopropyl derivatives and methods of use
WO2011161295A3 (en) Use of anticalcineurin compounds for the treatment of pathologies involving ocular neovascularisation
WO2014147578A3 (en) Antibacterial compounds against drug resistant bacteria
MX2016003347A (en) USE OF 3-CARBOXY-<i>N</i>-ETHYL-<i>N</i>,<i>N</i>-DIMETHYLPROPAN- 1-AMINIUM OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF IN THE PREVENTION AND TREATMENT OF DIABETES.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13775534

Country of ref document: EP

Kind code of ref document: A2

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 26/03/2015)

122 Ep: pct application non-entry in european phase

Ref document number: 13775534

Country of ref document: EP

Kind code of ref document: A2